Fundación Universitaria de Ciencias de la Salud
12
1
1
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
25.0%
3 terminated/withdrawn out of 12 trials
66.7%
-19.8% vs industry average
33%
4 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Altitude and Outcomes in Pediatric ARDS: A Multicenter Study
Role: collaborator
Impact of Colchicine in Hospitalized Colombian Patients With COVID-19
Role: lead
Is Red Blood Cell Transfusion a Risk Factor for Vascular Pedicle Thrombosis? The Study Case of a Latin American Cohort
Role: lead
Evaluation of a Non-face to Face Multidisciplinary Health Care Model in a Population With Rheumatoid Arthritis
Role: lead
Convalescent Plasma for Patients With COVID-19: A Randomized, Single Blinded, Parallel, Controlled Clinical Study
Role: collaborator
Convalescent Plasma for Patients With COVID-19: A Pilot Study
Role: collaborator
Safety and Efficacy of Mesenchymal Stem Cells in the Management of Severe COVID-19 Pneumonia
Role: collaborator
Controlled Sedation for Cataract Surgery
Role: lead
A Semi-structured Interview PACIENTE Improves Communication With Family Members at the Intensive Care Unit
Role: lead
Pharmacodynamic Differences Between Branded and Unbranded Remifentanil Molecules
Role: lead
Pilot Study of a Nerve Block Simulator for the Training in Axillary Blocks
Role: lead
Remifentanil Versus Propofol for TCI Sedation of Patients Undergoing Gastrointestinal Endoscopic Procedures
Role: lead
All 12 trials loaded